Human Papillomavirus Vaccine(Zhejiang Pukang Biotechnology)

Primary objective: To evaluate the safety and tolerability of different doses of human papillomavirus type 16 recombinant adenovirus vector vaccine in adult women (25-45 years old) who are persistently infected with human papillomavirus type 16. Secondary objective: To preliminarily explore the immunogenicity of different doses of human papillomavirus type 16 recombinant adenovirus vector vaccine.